MDACC Study No:2012-0470 ( NCT No: NCT01673737)
Title:A Phase I/Ib study for the evaluation of SAR260301, administered orally in
monotherapy in patients with advanced solid tumors or lymphomas, and in
combination with vemurafenib in patients with unresectable / metastatic BRAF
mutated melanoma.
Principal Investigator:Michael Davies
Treatment Agent:SAR260301
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of the drug SAR260301 when it is given alone or in combination with
vemurafenib. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:SAR260301
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sanofi-Aventis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Davies
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults